Osimertinib

https://www.drugs.com › mtm › osimertinib.html
What is osimertinib Osimertinib is used to treat non small cell lung cancer that is positive for an abnormal EGFR gene You doctor will test you for this gene Osimertinib is sometimes given

https://www.ema.europa.eu › en › medicines › human › EPAR › tagrisso
The active substance in Tagrisso osimertinib is a type of cancer medicine called a tyrosine kinase inhibitor It blocks the activity of EGFR which normally controls the growth and

https://www.macmillan.org.uk › ... › treatments-and-drugs › osimertinib
What is osimertinib Tagrisso Osimertinib is also called Tagrisso It is a type of drug called a tyrosine kinase inhibitor TKI It belongs to a group of targeted therapy drugs known as cancer

https://www.nejm.org › doi › full
Osimertinib is a third generation epidermal growth factor receptor tyrosine kinase inhibitor EGFR TKI that is selective for EGFR TKI sensitizing and EGFR T790M resistance mutations

https://www.mayoclinic.org › drugs-supplements › ...
Osimertinib is used to treat non small cell lung cancer NSCLC in patients who have certain types of abnormal epidermal growth factor EGFR genes This medicine is used to prevent

https://www.cancerresearchuk.org › ... › drugs › osimertinib
Osimertinib is a type of targeted cancer drug It is a treatment for non small cell lung cancer NSCLC Find out about how you have it possible side effects and other important information

https://www.bccancer.bc.ca › drug-database-site › Drug...
Osimertinib A third generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor mutated non small cell lung cancer with the acquired Thr790Met mutation

https://www.sciencedirect.com › topics › medicine-and-dentistry › osimertinib
Osimertinib is defined as a mono anilino pyrimidine compound that irreversibly binds to the EGFR kinase domain specifically targeting the cysteine 797 residue in the ATP binding site and

https://www.nejm.org › doi › full
The primary analysis of this trial showed that first line treatment with osimertinib plus chemotherapy with a platinum based agent and pemetrexed led to significantly longer progression